Method of producing cephalosporins

专利摘要:
Compounds of the formula <IMAGE> I wherein R1 is hydrogen or a conventional amino-protecting group, R2 and R3 each are independently methyl or ethyl, and R4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, allyl, 2-butenyl, 3-butenyl, 2-hydoxyethyl, 3-hydroxypropyl, 2-(dimethylamino)ethyl, pyridylmethyl, pyridylethyl, benzyl or phenethyl, and nontoxic pharmaceutically acceptable acid addition salts and solvates thereof, as well as processes for their preparation, are disclosed. The compounds in which R1 is hydrogen are potent antibacterial agents.
公开号:SU1373325A3
申请号:SU843720792
申请日:1984-04-02
公开日:1988-02-07
发明作者:Камати Хадзиме；Окумура Юн；Наито Такаюки
申请人:Бристоль Мейерз Компани (Фирма)；
IPC主号:

专利说明:


cm
This invention relates to the field of production of new cephalosnorinic derivatives of the common forgula.
ABOUT
II S
-C-C-l H-r-Y 1
6 (CDC1
N
R
 l NMR spectrum blCDCl), ppm: 3.50 (2H, S); 4.02 (3N, S); 4.33 (2H, S) ;, 4.98 (lH, d); 5.87 (IH, q); 6.65 (IH, S); 6.90 (IH, S); 7.3 (25H, m).
P p and M ep 2, Benzhydride-3-iodine- V. il 1 III nu-KT numethyl-7-C (g) -2-methoxyimino-2- (2-three11 J Ins N «# rin IN-L / ni -,
u M X 4f (j Ithylaminothiazol-4-yl; acetami Do | -3-ce VH,
where R is methyl or ethyl;
ten
-zmethyl, ethyl, 2-hydroxyethyl,
20
25
2- (dimethylamino) ethyl, allyl
or 3-pyridylmethyl,
exhibiting antibacterial activity against gram-positive and gram-negative bacteria.
The aim of the invention is to develop, on the basis of known methods, a method for the production of new non-toxic cephalosporin compounds with valuable pharmacological properties.
Example 1. Benzhydryl3-chloro-MeTim-7-t (Z) -2-methoxyimipo-2- (2-tritylamiothiazol-4yl) acetamido-3 cephem-4-carboxylate.
The resulting benzhydryl-7-amino-3-. Chlormetsh1-3-cephem-4-carboxylate (2.29 g, 5.52 mmol) in (57 ml) is treated with bis (trimethylsilyl) adde-amnd (.- / ,, 4.09 ml, 16.6 mmol) at room temperature for 50 minutes, resulting in a clear solution. To this solution is added a solution of hydrochloric acid, which is derived from (Z) -2-MeT oxyimino-2- (2-tritylaminothiazol-4-yl) acetic acid (2.04 g, 4.60 mmol) and PC1g (1.15 g, 5.52 mmol 40 in methylene chloride (20 ml). The mixture is stirred at room temperature for 30 minutes, poured into cold water (200 ml) and extracted with ethyl acetate (ZlOO ml). The combined extracts are washed with aqueous KaCl solution, dried and evaporated. The syrup remaining after evaporation (4 g) is subjected to chromatographic separation in a column with syrup (150 g) using g elyunrovani mixtures of toluene and ethyl acetate first in a ratio of 10: 1 and then 3:. 1 Fractions containing the target soedifem-4-carboxylate.
A mixture of the 3-chloromethyl derivative obtained in Example 1 (1.50 g, 1.79 mmol) and NaJ (1.34 g, 8.98 mmol) in methyl ethyl ketone (80 ml) was stirred at room temperature for 15 minutes. 1 hour. After evaporation of the solvent, the residual product of evaporation is dissolved in ethnyl acetate (100 ml) and washed with water, an aqueous solution of Na SijOj and an aqueous solution of NaCl, dried and evaporated. The result is a target compound (1.47 g, 89%) in as an amorphous powder.
NMR spectrum b (CBC1), ppm: 3.55 (2H, ABq); 4.00 (3N, S); 4.25 (2H, K); 4.97 (1H, d); 5.80 (IH, q); 6.65 (IH, S); 6.90 (IH, S); 7.3 (25H, ra).
Froze 7-1 (g) -2- (2-Amino-20 thiazol-4-yl) -2-methoxyiminoacetamido T-3- (trimethylammonium) methyl 3-cephem-4-carboxylate. (compound I).
35
45
50
55
A 1 M solution of trimethylamine in di-methyl ether (1 ml, 1 mmol) was added to a stirred suspension of benzhydryl-3-iodomethyl-7-1 (X) -2-methoxyimino-2- (2-tritylaminothiazol-4 -yl) -acetamido1-3-cephem-4-carboxylate (468 mg, 5 mmol) in diethyl ether (30 ml) and the mixture is stirred for 1.5 hours. The precipitated quaternary salt is recovered by filtration (410 mg, yield 82%) and 3 ml of trifluoro-acetic acid (TFA) was added to it. The mixture is stirred for 1, 5 hours at room temperature; temperature and evaporated to dryness in vacuum at a temperature below 20 ° C. The evaporation residue is stirred with ether and the precipitated TFA salt is recovered by filtration (yield 365 mg), dissolved in a small amount of methanol and subjected to chromatographic separation in a column resin, nR-20, column dimensions 1.8 x 20 cm). Elution was carried out with water (about 1 L) and then with 30% aqueous methanol (0.5 L).
The mixture is combined and evaporated to give 2.61 g (68%) of the title compound as an amorphous powder.
2
6 (CDC1
NMR spectrum blCDCl (2H, S); 4.02 (3N, S); 4.98 (lH, d); 5.87 (IH (IH, S); 6.90 (IH, S);
Tylaminothiazol-4-yl; AcetamiTo | -3-ce0
20
25
40
fem-4-carboxylate.
A mixture of the 3-chloromethyl derivative obtained in Example 1 (1.50 g, 1.79 mmol) and NaJ (1.34 g, 8.98 mmol) in methyl ethyl ketone (80 ml) was stirred at room temperature for 5 hours. 1 hour. After evaporation of the solvent, the residual product of evaporation is dissolved in ethnyl acetate (100 ml) and washed with water, an aqueous solution of Na SijOj and an aqueous solution of NaCl, dried and evaporated. The result is a target compound (1.47 g, 89%) in as an amorphous powder.
NMR spectrum b (CBC1), ppm: 3.55 (2H, ABq); 4.00 (3N, S); 4.25 (2H, K); 4.97 (1H, d); 5.80 (IH, q); 6.65 (IH, S); 6.90 (IH, S); 7.3 (25H, ra).
Froze 7-1 (g) -2- (2-Amino-20 thiazol-4-yl) -2-methoxyiminoacetamido T-3- (trimethylammonium) methyl 3-cephem-4-carboxylate. (compound I).
0
five
five
0
five
A 1 M solution of trimethylamine in di-methyl ether (1 ml, 1 mmol) was added to a stirred suspension of benzhydryl-3-iodomethyl-7-1 (X) -2-methoxyimino-2- (2-tritylaminothiazol-4 -yl) -acetamido1-3-cephem-4-carboxylate (468 mg, 5 mmol) in diethyl ether (30 ml) and the mixture is stirred for 1.5 hours. The precipitated quaternary salt is recovered by filtration (410 mg, yield 82%) and 3 ml of trifluoro-acetic acid (TFA) was added to it. The mixture is stirred for 1, 5 hours at room temperature; temperature and evaporated to dryness in vacuum at a temperature below 20 ° C. The evaporation residue is stirred with ether and the precipitated TFA salt is recovered by filtration (yield 365 mg), dissolved in a small amount of methanol and subjected to chromatographic separation in a column with resin nP-20, column dimensions 1.8 x 20 cm). Elution was carried out with water (about 1 L) and then with 30% aqueous methanol (0.5 L).
The methanol eluate is evaporated in vacuo at a temperature below and the evaporation residue is dried at a temperature below, resulting in a crude target product (yield 129 mg). The ratio of Lie isomers l in this product is 1: 2, which is determined by liquid chromatography under pressure. The drop product is purified by liquid chromatography under pressure (filler of a Lichrosorb-l8 column, column size mm, elution is carried out in 14% yield, which decomposes (pH 72) at a lower temperature.
is a mixture of 1/100 M ,, and SI, OH (ratio 85:15). The liquid chromatography eluate is subjected to separation in a chromatographic column filled with} iP-20 (column size 1 cm) in order to remove the inorganic salt. Elution of this column is carried out with water (0.5 L) and then with 30% aqueous methanol (0.5 L). The methanol eluate is evaporated in vacuo at a temperature below 4 () C and the evaporation residue is dried at a temperature below, resulting in a target compound 30
Product purity 80%.
Example 7-1 (Z) -2- (2-Aminothiazol-4-yl) -2-methoxyiminocetamine-2Q to -3-1H, G 1-dimethyl-M- (3-pyridylmethyl ammonium methyl-3-cephem 4-carboxylate.
The process is carried out as in Example 3, with the difference that, instead of trimethylamine, an equal amount of 3- (dimethylammonium / pyridine) is used. In the resulting product, the ratio of isomers L and (is 1: 4.3. After purification, the desired compound with a yield of 17%, which decomposes at a temperature above 170 C. The purity of the product is 75%.
in the form of an amorphous powder. The product yield is 75 mg (33% based on the starting product). This product slowly decomposes at temperatures above 160 C. The purity of the product is 80%.
IR spectrum "(KRG), 3600- 3000; 1775; 1660; 1610; 1540; 1350; 1030.
UV spectrum / MqKC (phosphate buffer solution, 1.15 M, pH 7,) nM it): 235 (15700); 257 (15400).
РR spectrum about (, ppm: 3.25 (911, S, Ы (СН) з); 4.10 (ЗН, S, ОСИ 5.47 (1Н, d, 4 Hz, 6-Н) ; 5.96 (1H, d, 4 Hz, 7-H); 7.10 (1H, S, thiazol-I).
PRI mme R 4. 7- (d) -2- (2-Aminothiazol-4-i.p) -2-methoxyiminocetateamide 3-1 g., G1-dimethyl-G1- (2-hydroxyethyl) ammonium 1methyl-3-cephem-4-carboxylate.
The process is carried out as in Example 3, with the difference that instead of trimethylamine an equal amount of 11, T1-dimethylethanolamine is used. In the resulting raw product, the ratio of isomers and (is 1: 2. After purification of the target compound, its output is
.7%, and it times
lag at a temperature of 160 ° C, product purity 90%.
II p and m e r 5. 7-f (/) -2- (2-Lminothiazol-4-yl) -2-methoxyiminolol-1 up to 1-3- (G1, N-dimethyl-and-allylammopy) methyl -Z-cephem-4-carboxylate.
The process is carried out as in Example 3, with the difference that instead of trimethylamine, equal amounts of N, N-dimethylally are used; amine The ratio of isomers / and lp raw product is 1: D, 5. After purification, the target compound is obtained.
0
Product purity 80%.
Example 7-1 (Z) -2- (2-Aminothiazol-4-yl) -2-methoxyimine-acetami-Q to -3-1H, G 1-dimethyl-M- (3-pyridylmethyl) ahymonium methyl-3-cephem -4-carboxylate. The process is carried out as in Example 3, with the difference that instead of trimethylamine, an equal amount of 3- (dimethylammonium / pyridine) is used. In the resulting crude product, the ratio of isomers L and (is 1: 4.3. After purification, the desired compound with a yield of 17%, which decomposes at a temperature above 170 C. The purity of the product is 75%.
Example 7. 7-L (Z) -2- (2-Aminothiazol-4-yl) -2-methoxyiminoacetamido-3-k, G1-dimethyl-G - (2-dimethylami-5 noethyl) ammonium J methyl 3-cepheme-4-c-boxylate.
The process is carried out as in Example 3, with the difference that instead of trimethylamine, use that equal amount of 1,2-bis (dimethylpmino) ethan. The ratio of isomers d and L in the raw product is 1: 1. After purification, the desired compound is obtained with a yield of 14%, which rises at temperatures above 150 C. The purity of the product is 65%.
EXAMPLE 8 7- (1, / - 2- (2-aminothiazol-4-yl, 1-2-methoxyimino acetamide-to-3- (N, K, -dimethyl-K-ethylammonium 1)
0 methyl-3-cephem-4-carboxylate.
The process is carried out as described in Example 3, with the difference that instead of trimethylamine, an early molar amount of K, 1 1-dimethyl 5 ethylamine is used. The ratio of L isomers and raw product is 1: 1. After purification, a pure compound is obtained with a yield of 15%, which time
The temperature is above 150 ° C. The purity of the product is 77%.
PRI me R 9. 7-1 (z) -2- (2-aminothiazol-4-yl) -2-methoxyiminoacetam-to-3-LN, N-diethyl-N-methyl ammonium) methyl -Z-cephem-4-carboxylate.
The process is carried out as described in Example 1, with the difference that a uniform amount of diethylmethylamine is used instead of trimethylamine. The ratio of isomers L and 1 in the raw product is 1: 1. After purification, the desired compound is obtained in a yield of 10%, which decomposes at a temperature above 150 ° C. The purity of the product is 65%.
Corresponding to) 1) isomeric L and A in the resulting raw, product is 3: 1. After purification, the desired compound is obtained in a yield of 3%, which decomposes at a temperature above 150 C. The purity of the product is 70%.
Spectral analysis of the compounds of Examples 3-9 is carried out.
IR spectrum data (K}; d) - all products have similar infrared spectra, cm 1770-1775 (p-lactam); 1660 (sleep); 1610 (CCA-).
UV spectrum data 1/15 M, phosphate buffer solution; pH 7) - all products, with the exception of the product from example 4, show the same spectra, nm: 235 (t15700-16AOO); 257 (fc 1 5400-1 6000; compound 4 shows the following spectra, nm: 235 (L 17600); 255 (t 18600; Sh); 260 (t 19000); 266 (t 179000, Sh).
Compounds I exhibit high antibacterial activity against various gram-positive and gram-negative bacteria.
In the initial assessment of the most preferred compound I, as well as for compounds that are similar in structure and purpose, the geometric mean minimum inhibitory concentration (M1G) was determined for in vitro tests for 11; th compound in three groups of gram-positive and gram-negative microorganisms, as well as a protective dose (SL) obtained in in vivo tests.
DS11P {s are listed in Table. one.
five
five
As can be seen from the table. 1, cefotaxime shows good activity against (0 +) - 1a, (C4 -) - 1b, (G -) - la and (G -) - lb microorganisms, but mediocre
activity (MIC-23 mg / ml) against (G -) - IIT (Pseudomonas aerupinosa). Ceftazidime exhibits very good activity against (G -) - IIT (Pseudomona .s aeruginosa), but is less active against (G +) -la, (G +) - lb, (G -) - la and; (G -) - nj of microorganisms, although its activity against (G -) - la BL-niie. Compound A exhibits good activity against (G +) - la, (G +) - lb, (G -) - la, (G -) - lb and (G -) - II microorganisms, but moderate activity against (G -) -IIT (Pseudomonas aeruginosa). Compound B is less active against (G -) - III microorganisms. Compound I, on the other hand, shows good activity against each of the gram-positive and gram-negative microorganisms, including Pseudomonas aeruginosa. With respect to (G -) - III microorganisms, compound I is twice as active as compound A, and more than three times as active as compound B. In addition, higher in vitro activity is evidence for transfer to in-treatment methods. v-ivo. Thus, the values of the protective dose of Zd d for mice against Pseudom aerug. indicate that compound I is 2.5 times more active than compound A and B.
Absorption in the body of the compound itself) and I were determined in mice by performing one intramuscular injection of the test compound (dissolved in 0.1 N phosphate buffer solution; RP 7) at a dose of 20 mg / kg. Samples of blood cells were taken from the cavities of the heparinated capillary tubes and determined in Kuceller-Hinton medium using Morganella morganii A 9695 as the test organism. Content
5Q of the drug in the blood in different} 1st periods of time, the half-life of the drug and the area under the curve (AUC) are given in Table. 2
0
five
0
The activity of action I in vitro against 31 strains of different types; bacteria were determined on GG agar, the results obtained are presented in Table. 3
H, NA7lt
-sn,
, 0.30 0.8 0.0095 0.079 0.53
Cefotaxin-CH
.
-Russ
1.2
iefta51 | dim-С (СI,), СОО-М,
4.8
Note (0) is sensitive to penicillin S. aure-js (5 watts); tG) -lb - penicillin-resistant P. igeiv (5 ptamn); (C -) - 1a - sensitive to cefdlogin K. coli (2 states)) HI. pnnunoninf (I ptakn) and Ps, mlrabills (2 strain); (G -) - lb - resistant to tse4 allotin E. r: oli (3 ptamna) and K1, pneur.oniae (3 ptamnp); (G -) - IT - Or. morf.anll (I shta)), Knt. clnni-.f (2 pt kma) n Rcr. marceec. (2); (n -) - III - Re. aeruginoia
II
0.03916,}
0.022 0.40
4.8
25
0.94580
0.076 2.0
2.8
2.0 0.11
S,
137332510
Food-xkeine Table 2
ZZZI ZIZ L Z
50 4.7 604.4
901.5
1200.74
1/224
AUC, mcg.h / ml10
Table 3

Test organism Medium geo- (number of strains) metric
MIC values
MG1S / ML
S. pyogenes (6) 0.013
S..pneumonial (6) 0.013
N. gonorihoeae (4) 0.013
N. meningitides (5) 0,016
N. influenzae (7) 0.013 (ampicillin sensitive)
N. influenzae (W) (resistant to ampicillin).
0.20

权利要求:
Claims (1)
[1]
The claims
The method of obtaining cephalosporins of the General formula where R R
ΘΙ ¹ CH2-N-CH ₃ ⁵ * 2 osn ₃ methyl or ethyl; methyl, ethyl, 2-hydroxyethyl, 2- (dimethylamino) ethyl, allyl or 3-pyridylmethyl, resulting in the fact that benzhydryl-7-amino-3-chloromeO T L is a mixture of tyl-3-cefem-4-carboxylate and bis ( trimethylsilyl) acetamide is reacted with (Z) -2-
1373325 8 methoxyimino-2- (2-tritylaminothiazol4-yl) acetic acid in an organic solvent, the resulting 3-chloromethyl-3-cefem derivative is affected by an alkali metal iodide salt in an organic solvent, the resulting 3-iodomethyl-3-cefemic the derivative I is treated in an organic solvent with trimethylamine or Ν, Ν, dimethylethanolamine, or Ν, Ν-dimethylallylamine, or 3- (dimethylaminomethyl) pyridine, or 1,2-bis (dimethylamine) ethane, or Ν, Ν-dimethylethylamine or diethyl followed by removing the benzhydryl group protecting the carboxyl, acid hydrolysis and isolating the target. product.
Table 1
C-CONHOX
Compound
Following the example
Cefotaxime
Ceftazidime
X At Geometric mean KIK value, μg / ml (from Evil mg / kg (dm _β mavi) (0 +) - 1, | (0 +) - 1b(0 -) - 1b (o -) - n K. eoli Ra, aerugi-nosa -sn J -NICHjHzb 0,033 0,0250.69 3.2 0.015 7.2 '• CHj^f th 0.56 1.3 0,032 0.231.1 5.8 0,039 18 -sn ₃ 0.30 0.8 0.0095 0,0790.53 eleven 0,039 16.5 -CH ₃-OCCHj '1.2 3.1 0,022 0.40'.8 25 * 0.945 80 -s (sn), soon 4.8 ’2.5 0,076 2.02,8 2.0 0.11 5.4
Note: (С * *) - 1а - sensitive to penicillin S a aureus (5 vitamin); XG *) - lb - resistant to penicillin S, aureus (5 mtm); (G -) - la - x sensitive to cephalotin F, coll (2 zhtammd); Hl. rneunomiae (I πτβ> · ι) and Ps. nirabilis (2 retracts); (G -) - lb - resistant to cephalotin E. coli (3 Wtm) and K1 “pneunoniae (3 Ptm); (G-) · II - Or, morf.anli (I '* ....
(6
zhtm), Ent, clonce (2 vtmah) and Ser, tageevs. (2 times> x <a); (G-) tamm), For compound A, the geometric mean value of THEM table 2 ----------— Time interval The content of the compound is min after input I in the blood mcg / ml 1 2 10 14 20 12 thirty 8.8 40 7.5
ΊΪ1 - Ps. aeruginosa: of three proO.
1373 325 10
Continuation of Table 2
'- i 2 fifty 4.7 60 4.4 90 1,5 120 0.74 1/2 24 AUC, mcg / ml 10 T a b l c a 3 Test organism Medium geo (number of strains) MIC metric values, mg / ml S. pyogenes (6) 0.013 S..pneumonial (6) 0.013 N. gonorihoeae (4) 0.013 N. meningitides (5) 0.016 H. influenzae (7) 0.013 (sensitive to ampicillin) H. influenzae (3)(resistant to ampicillin). 0.20

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1373325A3|1988-02-07|Method of producing cephalosporins

---

SU1303029A3|1987-04-07|Method for producing derivatives of cephalosporin

---

DE2129675C3|1981-07-09|7-methoxycephalosporin derivatives, processes for their preparation and medicaments containing them

---

EP0186187B1|1992-02-26|Cephalosporin derivatives

---

SU1367858A3|1988-01-15|Method of producing cephalosporin derivatives

---

US5151417A|1992-09-29|3-substituted vinyl cephalosporin derivatives

---

US5081116A|1992-01-14|Cephalosporin derivatives

---

HU193158B|1987-08-28|Sposob poluchenija 3,7-dizamehhennykh proizvodnykh 3-cefem-4-karbonovykh kislot

---

US4866055A|1989-09-12|Cephalosporin derivatives and their crystalline derivatives

---

EP0560365B1|1997-09-24|Cephalosporin derivative

---

AT390956B|1990-07-25|METHOD FOR PRODUCING NEW, 3-POSITIONED PROPENYLAMINOTHIAZOLYLCEPHALOSPORANIC ACIDS AND THEIR ESTERS

---

US5587473A|1996-12-24|7-acyl-3-| cephem compounds and process for their preparation

---

US5142041A|1992-08-25|Cephalosporin intermediates

---

US5332731A|1994-07-26|Cephalosporin derivatives

---

US5464829A|1995-11-07|Cephalosporin derivatives

---

US4929612A|1990-05-29|Thiadiazolylacetamide cephem derivatives

---

EP0304036A2|1989-02-22|3-|propenyl-7-|ceph-3-em-4-carboxylic acids and esters thereof

---

EP0553792B1|1999-05-26|Process for the preparation of the disodium salt hemiheptahydrate of ceftriaxone

---

JP3045518B2|2000-05-29|Carbapenem derivatives

---

AT389515B|1989-12-27|Process for the preparation of novel cephalosporin compounds

---

SU1326195A3|1987-07-23|Method of producing 7-/2-|-/z/-2-|acetamido/-3-/|methyl/-3-cephem-4-carboxylate

---

US4497811A|1985-02-05|1-Oxadethiacephalosporin compound and antibacterial agent containing the _same

---

US5120728A|1992-06-09|Cephalosporin compounds

---

JP2662414B2|1997-10-15|Thiazole derivatives

---

EP0098615B1|1988-01-07|1-oxadethiacephalosporin compound and antibacterial agent containing the same

同族专利:

---

公开号 | 公开日

---

SE453092B|1988-01-11|

---

AU1186483A|1983-10-06|

---

DK161024C|1991-10-28|

---

GB2117770A|1983-10-19|

---

ES8504205A1|1985-04-16|

---

MY8700944A|1987-12-31|

---

SE8301726D0|1983-03-28|

---

GB2117770B|1985-10-09|

---

KR840004119A|1984-10-06|

---

IT8348006D0|1983-03-28|

---

FR2523973A1|1983-09-30|

---

PT76460B|1986-03-11|

---

DK95383A|1983-09-30|

---

FI831013L|1983-09-30|

---

DE3311300C2|1991-05-16|

---

AT383129B|1987-05-25|

---

FI831013A0|1983-03-24|

---

SE8301726L|1983-11-25|

---

ES520983A0|1985-10-01|

---

ATA110983A|1986-10-15|

---

ES527661A0|1985-04-16|

---

IE830687L|1983-09-29|

---

KR900005047B1|1990-07-18|

---

US4457929A|1984-07-03|

---

CS219083A2|1988-09-16|

---

GR77907B|1984-09-25|

---

CS264257B2|1989-06-13|

---

DK161024B|1991-05-21|

---

IL68244D0|1983-06-15|

---

FR2523973B1|1986-09-12|

---

ES8600312A1|1985-10-01|

---

PT76460A|1983-04-01|

---

DK95383D0|1983-02-25|

---

EG16029A|1987-03-30|

---

SU1205772A3|1986-01-15|

---

YU43654B|1989-10-31|

---

BE896292A|1983-09-28|

---

GB8308519D0|1983-05-05|

---

DD210279A5|1984-06-06|

---

NL8301053A|1983-10-17|

---

AU564971B2|1987-09-03|

---

OA07354A|1984-08-31|

---

ZA832156B|1984-08-29|

---

FI74974B|1987-12-31|

---

PH18959A|1985-11-26|

---

CH655118A5|1986-03-27|

---

IE54791B1|1990-02-14|

---

JPS58198490A|1983-11-18|

---

NZ203360A|1985-08-16|

---

FI74974C|1988-04-11|

---

HU189676B|1986-07-28|

---

LU84717A1|1983-12-05|

---

YU71683A|1986-02-28|

---

SU1313351A3|1987-05-23|

---

CA1213883A|1986-11-12|

---

DE3311300A1|1983-09-29|

---

IT1164634B|1987-04-15|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1399086A|1971-05-14|1975-06-25|Glaxo Lab Ltd|Cephalosporin compounds|

---

GB1536281A|1975-06-09|1978-12-20|Takeda Chemical Industries Ltd|Cephem compounds|

---

GR63088B|1976-04-14|1979-08-09|Takeda Chemical Industries Ltd|Preparation process of novel cephalosporins|

---

DE2714880A1|1977-04-02|1978-10-26|Hoechst Ag|CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION|

---

ES485435A1|1978-10-27|1980-07-01|Glaxo Group Ltd|Cephalosporin antibiotics|

---

ZA795736B|1978-10-27|1980-10-29|Glaxo Group Ltd|Cephalosporin compounds|

---

GR78245B|1980-09-12|1984-09-26|Ciba Geigy Ag|US4963542A|1976-09-08|1990-10-16|Takeda Chemical Industries, Ltd.|Cephalosporin derivatives|

---

US6572872B2|1989-09-01|2003-06-03|Battelle Memorial Institute|Method and apparatus for providing long term protection from intrusion by insects and other cold blooded animals|

---

US5925368A|1981-10-26|1999-07-20|Battelle Memorial Institute|Protection of wooden objects in direct contact with soil from pest invasion|

---

US6099850A|1981-10-26|2000-08-08|Battelle Memorial Institute|Termite and boring insect barrier for the protection of wooden structures|

---

US6060076A|1981-10-26|2000-05-09|Battelle Memorial Institute|Method and apparatus for providing long term protection from intrusion by insects and other cold blooded animals|

---

US6331308B1|1981-10-26|2001-12-18|Battelle Memorial Institute|Method and apparatus for providing long term protection from intrusion by insects and other cold blooded animals|

---

US6852328B1|1989-09-01|2005-02-08|Battelle Memorial Institute K1-53|Method and device for protection of wooden objects proximate soil from pest invasion|

---

US6319511B1|1989-09-01|2001-11-20|Battelle Memorial Institute|Termite and boring insect barrier for the protection of wooden structures|

---

US4525473A|1983-03-30|1985-06-25|Bristol-Myers Company|Cephalosporins|

---

DE3409431A1|1983-10-08|1985-04-18|Hoechst Ag, 6230 Frankfurt|CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION|

---

DE3419012A1|1984-05-22|1985-11-28|Bayer Ag, 5090 Leverkusen|SS LACTAMANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS OR GROWTH SUPPORTERS IN ANIMAL GROWING OR AS ANTIOXIDANTS|

---

GB8424692D0|1984-10-01|1984-11-07|Glaxo Group Ltd|Chemical compounds|

---

EP0182210B1|1984-11-12|1991-02-27|Banyu Pharmaceutical Co., Ltd.|Cephalosporin derivatives|

---

US4868173A|1984-11-20|1989-09-19|Ici Pharma|Cephalosporin derivatives|

---

US4883868A|1984-12-27|1989-11-28|Banyu Pharmaceutical Co., Ltd.|7-amino-3-methyl-3-cephem derivatives|

---

JPH068300B2|1985-08-02|1994-02-02|萬有製薬株式会社|New cefalosporin derivative|

---

IE862850L|1985-11-21|1987-05-21|Inst Animal Health Ltd|Intermediates for the preparation of beta-lactam antibiotics|

---

US4814328A|1986-03-19|1989-03-21|Banyu Pharmaceutical Co., Ltd.|Cephalosporin derivatives, and antibacterial agents|

---

IL84128A|1986-10-13|1992-12-01|Eisai Co Ltd|3-propenylcephem derivatives, their preparation and pharmaceutical compositions containing them|

---

US5244890A|1988-06-06|1993-09-14|Fujisawa Pharmaceutical Co., Ltd.|Cephem compounds|

---

GB9107973D0|1991-04-15|1991-05-29|Fujisawa Pharmaceutical Co|New cephem compounds and process for preparation thereof|

---

US5985304A|1998-02-25|1999-11-16|Battelle Memorial Institute|Barrier preventing wood pest access to wooden structures|

---

KR100380323B1|2000-01-26|2003-04-16|한국과학기술연구원|Synthesis of new cephalosporin derivatives with n-methyl-namino group|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/363,313|US4457929A|1982-03-29|1982-03-29|3-Quaternary ammonium methyl)-substituted cephalosporin derivatives|

---